Vigonvita Life Sciences Co., Ltd. (蘇州旺山旺水生物醫藥股份有限公司, Stock Code: 2630) announced that the stabilization period for its Global Offering concluded on December 3, 2025. According to the company, there was no over-allocation of H Shares in the International Offering, and no stabilizing actions took place during the stabilization period.
The Sponsor-Overall Coordinator did not exercise the Over-allotment Option before it lapsed on December 3, 2025, resulting in no additional H Shares being issued. The company stated that it continues to meet the public float requirement under Rule 19A.13A of the Listing Rules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments